Molecular epidemiological analysis of prostate cancer in Hunan population

Molecular epidemiological analysis of prostate cancer in Hunan population and research on the intervention of warming the kidney and promoting blood circulation and detoxification

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200005999

Enrollment

Unknown

Registered

2022-05-12

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

The high risk group:Needle biopsy of prostate

Validation group:Massage to get prostate fluid

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with undetermined or unknown prostate dynamic tumors requiring prostate needle biopsy. ? Suspicious prostate nodules on digital rectal examination, any prostate-specific antigen values; ? Transrectal prostate ultrasound or MRI found suspicious lesions with normal prostate-specific antigen; ? Prostate specific antigen > 10 ng/ mL; ? Prostate-specific antigen was 4-10 ng/ mL, and free prostate-specific antigen/total free prostate-specific antibody (fPSA/tPSA) was suspicious. Patients in line with the first two criteria should undergo prostate puncture biopsy regardless of the value of psa.

Exclusion criteria

Exclusion criteria: ? Patients who have been diagnosed with prostate cancer; ? Patients with serious heart, brain, liver and kidney diseases and intolerance to prostate biopsy; ? Those who are unwilling to receive needle biopsy of prostate.

Design outcomes

Primary

Measure	Time frame
Differential metabolites;	—

Countries

China

Contacts

Public ContactZHOU Qing

supergoon@163.com13574855248

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026